Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904540 · ClinicalTrials.gov registry record · Phase 4
Topical Lidocaine Patch in Low Back Pain
A Phase 4 study of Acute and Chronic Non-radicular LBP, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
- 7
- Study locations
NCT00904540: Completed Phase 4 study of Acute and Chronic Non-radicular LBP, sponsored by Endo Pharmaceuticals.
NCT00904540 is a Phase 4 study of Acute and Chronic Non-radicular LBP that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 131 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904540, a Phase 4 study of Acute and Chronic Non-radicular LBP, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
- 7
- Study locations
Study Summary
Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.
Conditions Studied
Interventions
- DRUG Lidoderm®
Study Locations (7)
Arizona
- - Phoenix
California
- - Mill Valley
Florida
- - Weston
New York
- - Bethpage
North Carolina
- - Charlotte
Pennsylvania
- - Allentown
Wisconsin
- - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2002-03 |
| Phase | Phase 4 |
What the finished NCT00904540 record still lists
NCT00904540 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Acute and Chronic Non-radicular LBP appearing as the primary indexed condition, and to 1 intervention - of which Lidoderm® is the first listed.
NCT00904540 lists 7 locations in 7 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00904540 about?
NCT00904540 is a clinical study titled "Topical Lidocaine Patch in Low Back Pain". Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.
What is the current status of trial NCT00904540?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2002-03.
What conditions does trial NCT00904540 study?
This clinical trial studies the following conditions: Acute and Chronic Non-radicular LBP.
What interventions are being tested in trial NCT00904540?
The interventions under investigation include: Lidoderm® (DRUG).
Who is sponsoring clinical trial NCT00904540?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904540 being conducted?
This trial has 7 study locations across Arizona, California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00904540's enrollment target sits among peer trials
131 619th of 2000 higher than 1,380 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia